Home > Insider Trading > Filing (0001181431-14-000240)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1396814	Pacira Pharmaceuticals Inc.	PCRX	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1288231	Phd P John Longenecker	C/O Pacira Pharmaceuticals, Inc. 10450 Science Center Drive San Diego CA 92121		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2013-12-30	581	$1.61	581	No	4	M	Direct
Common Stock	Acquisiton	2013-12-30	1,345	$1.61	1,926	No	4	M	Direct
Common Stock	Acquisiton	2013-12-30	574	$1.61	2,500	No	4	M	Direct
Common Stock	Disposition	2013-12-30	2,500	$55.55	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2013-12-30	581	$0.00	581	$1.61
Common Stock	Stock Option (right to buy)	Disposition	2013-12-30	1,345	$0.00	1,345	$1.61
Common Stock	Stock Option (right to buy)	Disposition	2013-12-30	574	$0.00	574	$1.61

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
872	2020-09-02	No	4	M	Direct
0	2020-09-02	No	4	M	Direct
6,864	2020-09-02	No	4	M	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
The option vested as to 25% of the options on September 2, 2011 and vests as to the remaining options in successive equal monthly installments for the subsequent 36 months. The options became exercisable, to the extent vested, from and after the Issuer's initial public offering.
The option vested as to 50% of the options upon the first anniversary of the Issuer's initial public offering and as to the remaining 50% of the options upon the second anniversary of the Issuer's initial public offering. The options became exercisable, to the extent vested, from and after the Issuer's initial public offering.
The option vested as to 75% of the options on September 2, 2010 and vested as to the remaining 25% of the options in successive equal monthly installments for the subsequent 12 months. The options became exercisable, to the extent vested, from and after the Issuer's initial public offering.